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Spinal muscular atrophy (SMA) is a hereditary disease of the 
anterior horn cell in the spinal cord, which results in progres-
sive proximal muscle weakness. This autosomal recessive dis-
ease has a prevalence of approximately 1 in 10000 newborns. 
In the 1990s, the Survival Motor Neuron (SMN) gene was re-
vealed to be a key gene involved in SMA. The most common 
form of SMA is caused by homozygous deletions in the Surviv-
al Motor Neuron 1 (SMN1) gene accounting for about 95% of 
reported cases.1 Patients with SMA are typically classified into 
four subtypes according to age of onset and degree of severity: 
type I–IV. 2
Owing to its clinical similarity with congenital myopathy, 
clinicians have some difficulties in quick and direct diagnosis 
of SMA. Conventionally, electrophysiological tests, such as 
electromyography, and pathologic study by muscle biopsy are 
conducted as a primary study in patients with proximal domi-
nant symmetric progressive weakness. It is now advisable to 
analyze the SMN1 deletion along with electrophysiological and 
pathologic study in the initial assessment of typical SMA-like 
patients, since genetic diagnostic test can be easily performed 
and offers accurate diagnosis, with a sensitivity of up to 98%.2,3
With improvements in genetic analysis and novel therapeu-
tic approaches, such as gene therapy and molecular therapy, 
the diagnostic approach for patients with SMA is significantly 
important. We investigated the clinical and pathologic char-
acteristics of SMA cases confirmed by a genetic test in our hos-
pital.
This study is a single center oriented, retrospective, and de-
scriptive study. We first reviewed 42 patients referred to Gang-
nam Severance Hospital in Seoul from September 2007 to Feb-
ruary 2016 who had received SMN1 genetic test. Genetic analysis 
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of the deletion of exon 7 of the SMN1 gene on chromosome 
5q13 was performed by multiplex ligation-dependent probe 
amplification. After exclusion of 14 patients who showed no 
deletion of exon 7 or had little information in their medical re-
cords, we finally included 28 patients and reviewed their clini-
cal and pathological features from the medical records. Type 
of SMA was classified based on the age of onset as type I with 
onset before 6 months, type II from 6 to 18 months, and type 
III after 18 months.
Of the total 28 patients, there were 15 male and 13 female 
patients. Seven out of 28 patients had familial history with simi-
lar symptoms. Clinical types of SMA were distributed as 3 pa-
tients with type I, 14 patients with type II, and 11 patients with 
type III. All patients had proximal dominant symmetric weak-
ness regardless of the type of SMA. Eight patients showed dys-
phagia and 2 patients showed dysarthria. Two patients with 
type II and 1 patient with type III showed tongue fasciculation 
associated with dysarthria and ventilator care. Ventilator sup-
port was needed in 15 patients, including all 3 patients with type 
I, 8 patients with type II, and 4 patients with type III. Twenty-
five patients had scoliosis, and 8 of these patients, including 1 
patient with type I, underwent a surgical treatment for scolio-
sis with an improvement in clinical outcomes (Table 1).
Twenty-two patients underwent an electrodiagnostic study 
(EDS). Among them, 15 patients had both an EDS and muscle 
biopsy. Based on the clinical features together with EDS and 
muscle biopsy results, 9 patients were diagnosed with SMA, 
while the other 6 patients were diagnosed with myopathy (Ta-
ble 2). These 6 patients were later found to be misdiagnosed 
with myopathy (Table 3). Among them, we noted that EDS fi-
ndings were interpreted as myopathy in 4 patients and neu-
ropathy in 1 patient. One patient diagnosed at the age of 3 did 
not have an EDS. The clinical pattern of symmetric proximal 
dominant limb weakness was the same in all 6 patients. There-
fore, the EDS findings and clinical patterns together could have 
generated the confusion. These 6 patients were later confirmed 
to have SMA after SMN 1 gene mutation analysis. Of these pa-
tients who were misdiagnosed with myopathy before the ge-
netic study, it took as long as 11 years for these patients to 
achieve the correct diagnosis of SMA through a genetic study.
The spectrum of clinical severity of SMA ranges from infan-
tile paralysis causing premature death to mild motor weak-
ness and normal life expectancy. Generally, patients with SMA 
type I hardly survive until 48 months; however, according to 
recent reports, there have been some studies showing a de-
creasing mortality in SMA type I patients.4 In our study, three 
of the SMA type I patients had survived through the age of 20 
years at the last follow up, even though all of them required the 
use of a ventilator. These patients were all conservatively well-
managed from their infantile period through routine follow 
up in an outpatient clinic. Supportive care such as this includ-
ing respiratory support and surgical correction of scoliosis are 
very important for better clinical outcomes. Currently, there 
are no curative treatments that effectively alter the natural his-
tory of the disease. The goal of supportive care is to lessen the 
disease burden through managing symptoms and preventing 
complications. Adequate nutritional intake with physical thera-
py is important, and proper respiratory support is crucial since 
respiratory failure is a serious problem in patients with SMA 
type I and II. Noninvasive positive pressure ventilation may 
provide improved quality and life expectancy. 
The majority of patients who survive childhood develop pro-
gressive scoliosis, which worsens pulmonary function.5 How-
ever, few studies have demonstrated significant improvement 
after surgical correction of scoliosis.6 In our study, patients who 
had surgery to correct scoliosis showed improvements in pain 
relief, muscle strength during sitting or walking, frequency of 
respiratory infection, and some showed increase in vital ca-
pacity. These findings are similar to recent studies showing that 
surgical trunk alignment correction is essential to improve sit-
ting and standing tolerance, as well as pulmonary function, in 
SMA patients.7
In our study, weakness due to SMA preferentially involved 
Table 1. Baseline Characteristics of Patients with SMA
n (%) or mean (min–max)
Male:female 15 (54):13 (46)
Age at the time of symptom onset, month 33.8 (0–192)
Age at the time of diagnosis, yr 14.4 (0–49)
Clinical type of SMA
Type I 3 (11)
Type II 14 (50)
Type III 11 (39)
Family history 7 (25)
Clinical manifestations
Proximal-dominant weakness 28/28 (100)
Dysphagia 8 (28)
Dysarthria 2 (7)
Tongue fasciculation/atrophy 3 (10)
Scoliosis confirmed by radiography 25 (89)
Ventilator use 15 (53)
SMA, spinal muscular atrophy.
Table 2. Electrodiagnostic Study and Muscle Biopsy Findings of Pa-
tients with Spinal Muscular Atrophy
No. of patients (%)
Electrodiagnostic study (n=22)
Sensory nerve impairment (SNAP loss) 1 (4.5)
Positive sharp waves 16 (72.0)
Fibrillations 6 (27.0)
Giant MUAPs 11 (50.0)
Muscle biopsy (n=15)
Neurogenic atrophy 9 (60.1)
Myopathic change (including 1 end stage) 4 (26.6)
No pathologic diagnosis 2 (13.3)
SNAP, sensory nerve action potentials; MUAPs, motor unit action potentials.
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proximal muscles, in particular the lower extremities were the 
first involved. The clinical course of SMA can sometimes be 
confused with congenital myopathy. This clinical similarity 
leads clinicians to a misdiagnosis or delayed diagnosis for some 
patients.
Among the 22 patients in our study who underwent an EDS, 
many showed spontaneous activities, while some patients also 
had myopathic findings (Table 2). Among them, 15 patients 
had a muscle biopsy prior to genetic analysis. It is interesting 
that only 9 patients were diagnosed with neurogenic atrophy 
compatible to SMA, while 6 patients showed normal findings 
or had been misdiagnosed with myopathy. EMG results sh-
owing polyphasic motor unit action potentials together with 
clinical similarity could have led clinicians to misinterpret the 
pathologic findings of muscle biopsy. Also, the serum CK level 
did not show meaningful differences to help distinguish be-
tween SMA and myopathy (Table 3). These days, molecular ge-
netic analysis for the SMN1 gene deletion is becoming the gold 
standard diagnostic modality for correct diagnosis. Genetic 
analysis of the absence of SMN1 exon 7 confirms the diagnosis 
of SMA with 95% sensitivity and nearly 100% specificity.8 For 
this reason, we emphasize that the best approach for SMA di-
agnosis uses genetic analysis to detect a homozygous SMN1 de-
letion, which is a simple and non-invasive test.9
The limitations of this study are that only a small relevant 
population was included. Also, even though subgrouping of 
SMA is currently still done on a clinical basis, it would have been 
a better review with analysis of SMN2 gene copy number of 
patients. We could not determine the copy number of SMN2 
due to the lack of data. These days, the association between SMN2 
gene copy number and clinical phenotype in patients with SMA 
is well known, and its possible effect as a phenotype modifier 
is being examined.10,11 Even though SMN2 produces less of the 
full length protein transcript than SMN1, it is known the num-
ber of SMN2 copies affects the phenotype of SMA.12
This study reviewed the clinical phenotype and genetic dis-
tribution in patients with SMA who were diagnosed as having 
the SMN1 deletion by multiplex ligation-dependent probe am-
plification in Korea. Since upcoming novel gene therapy re-
quires a potential target for appropriate treatment, having prop-
er knowledge of the genetic profile of patients in the Korean 
database is important. Moreover, EDS and muscle biopsy con-
ducted before genetic analysis led to confusion and made the 
accurate diagnosis of SMA rather difficult, while the correct di-
agnosis was achieved with genetic mutational analysis. There-
fore, we emphasize that genetic analysis should be done early 
in the diagnostic process for patients with symmetric and proxi-
mal dominant weakness.
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